A Phase 3 interventional study of Paclitaxel and Bevacizumab in Ovarian Cancer, Fallopian Tube Cancer and Primary Peritoneal Cancer, sponsored by Hoffmann-La Roche. Completed at 16 sites in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-03.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 106 studies testing bevacizumab in Ovarian Neoplasms — 22 open to participants now, 32 under way, 9 of them phase 3. Bevacizumab · Ovarian Neoplasms.
Among the 106 studies testing bevacizumab in Ovarian Neoplasms, this one is the 34th largest by enrollment, is one of 5 that started in 2018, is one of 18 in phase 3, and was the 66th registered.
3,387 studies on the registry are indexed under Ovarian Neoplasms; 792 are open to participants now.
Browse Ovarian Neoplasms studies →22 of the 106 studies testing bevacizumab in Ovarian Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
CSPC Megalith Biopharmaceutical Co.,Ltd. · Sites in China
Ages 18+
Jiangsu Cancer Institute & Hospital · Sites in China
Ages 18–75
Medical University of South Carolina · Sites in United States
Ages 18+
Nanjing Leads Biolabs Co.,Ltd · Sites in China
Ages 18+
AbbVie · Sites in United States, Australia, Belgium and 5 more countries
Ages 18+ · Women only
By country, each count listing its studies:
Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →
Of the 605 Ovarian Neoplasms studies recruiting now, 442 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
106 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 73 · Phase 3 20 · Phase 4 2
First in 2003; this study’s year is marked. 5 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is above the median of 54 across 2,552 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 52 across the 106 interventional studies. Of the 60 that completed or were terminated, 37 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 106 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
35 studies in Ovarian Neoplasms by Hoffmann-La Roche: none open now, 3 under way, none of them phase 3. Of 31 finished, 14 (45%) have results posted.
Among the 35 studies in Ovarian Neoplasms by Hoffmann-La Roche, this one is the 15th largest by enrollment of the 30 interventional ones that give a count, is one of 2 that started in 2018, is one of 7 in phase 3, and was the 29th registered.
Hoffmann-La Roche’s Ovarian Neoplasms studies by the year they started, since 2001.
7 of the studies testing bevacizumab in Ovarian Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05445778Phase 3AbbVieMirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer | 2027-04 |
| NCT05636111M.D. Anderson Cancer CenterPhase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer | 2026-12-31 |
| NCT02884648M.D. Anderson Cancer CenterBevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery | 2027-02-02 |
| NCT07453394Qilu Pharmaceutical Co., Ltd.QLS5132 Combination Therapy in Advanced Solid Tumors | 2027-04 |
| NCT06799065Accent TherapeuticsFirst-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer | 2027-04-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 106 studies testing bevacizumab in Ovarian Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 35 in Ovarian Neoplasms:
This tab as a report to print or save as PDF → With an account.
This multicenter, double-blind, 2-arm, randomized study will evaluate the efficacy and safety of bevacizumab plus paclitaxel and caboplatin compared with placebo plus paclitaxel and caboplatin in Chinese participants with newly diagnosed, previously untreated Stage III or Stage IV epithelial ovarian, fallopian tube, or primary peritoneal cancer. Participants whose disease has not progressed after six cycles of paclitaxel and carboplatin with either bevacizumab or placebo will continue treatment with either bevacizumab or placebo until disease progression, unacceptable toxicity, or a maximum of 22 cycles, whichever occurs first.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive paclitaxel, carboplatin intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles. Bevacizumab IV infusion will start at Cycle 2 for 5 cycles, followed by maintenance therapy up to a maximum of 22 cycles or until disease progression, unacceptable toxicity, or withdrawal, whichever occurs first.
Drug: Paclitaxel · Drug: Bevacizumab · Drug: Carboplatin
Participants will receive paclitaxel, carboplatin IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles. Placebo IV infusion will start at Cycle 2 for 5 cycles, followed by maintenance therapy up to a maximum of 22 cycles or until disease progression, unacceptable toxicity, or withdrawal, whichever occurs first.
Drug: Paclitaxel · Drug: Carboplatin · Drug: Placebo
175 mg/m\^2 IV infusion on Day 1 of each 21-day cycle.
15 mg/kg IV infusion on Day 1 of each 21-day cycle.
Also known as: Avastin
Area Under the Curve (AUC) of 6 mg/ml/min on Day 1 of each 21-day cycle.
Placebo matched to bevacizumab IV infusion on Day 1 of each 21-day cycle.
Progression-Free Survival (PFS)
PFS was defined as time from randomization to the first occurrence of disease progression, as assessed by the Investigator using RECIST v1.1, or death from any cause, whichever occurs first.
Time frame: Randomization up to disease progression or death from any cause, whichever occurs first (up to approximately 24 months)
Overall Survival (OS)
OS was defined as the time from the date of randomization to the date of death from any cause.
Time frame: Randomization up to to death from any cause (up to approximately 54.1 months)
Objective Response Rate (ORR)
ORR was defined as the proportion of participants with complete response (CR) or partial response (PR) as assessed by investigator according to RECIST v.1.1.
Time frame: Randomization up to disease progression or death from any cause, whichever occurs first (up to approximately 24 months)
Duration of Response (DOR)
DOR was defined as the time from when response (CR or PR) was first documented to first documented disease progression,as assessed by the Investigator using RECIST v1.1, or death from any cause, whichever occurred first. DOR was evaluated for participants who had a objective response of CR or PR.
Time frame: From the date of first occurrence of a complete or partial response until disease progression or death from any cause (up to approximately 24 months)
Percentage of Participants Who Report a Clinically Meaningful Improvement in Patient-Reported Abdominal Pain
A clinically meaningful improvement in patient-reported abdominal pain or bloating was defined as a ≥10-point decrease from the linearly transformed 0-100 point baseline symptom scale score on each of two items from the Abdominal/Gastrointestinal Symptom Scale of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Ovarian Cancer Module (QLQ-OV28).
Time frame: From randomization to the end of treatment/discontinuation (up to approximately 70 weeks), and during follow-up period (up to approximately 24 months)
Percentage of Participants Who Report a Clinically Meaningful Improvement in Patient-Reported Bloating
A clinically meaningful improvement in patient-reported abdominal pain or bloating was defined as a ≥10-point decrease from the linearly transformed 0-100 point baseline symptom scale score on each of two items from the Abdominal/Gastrointestinal Symptom Scale of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Ovarian Cancer Module (QLQ-OV28).
Time frame: From randomization to the end of treatment/discontinuation (up to approximately 70 weeks), and during follow-up period (up to approximately 24 months)
Percentage of Participants Who Report a Clinically Meaningful Improvement in Patient-Reported Function (Physical)
A clinically meaningful improvement in patient-reported function and HRQoL was defined as a \>10-point increase from the linearly transformed 0-100 point baseline scale score on each of the four functional (physical, role, emotional, social) scales and global health status/HRQoL scale of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 (QLQ-C30).
Time frame: From randomization to the end of treatment/discontinuation (up to approximately 70 weeks), and during follow-up period (up to approximately 24 months)
Percentage of Participants Who Report a Clinically Meaningful Improvement in Patient-Reported Function (Role)
A clinically meaningful improvement in patient-reported function and HRQoL was defined as a \>10-point increase from the linearly transformed 0-100 point baseline scale score on each of the four functional (physical, role, emotional, social) scales and global health status/HRQoL scale of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 (QLQ-C30).
Time frame: From randomization to the end of treatment/discontinuation (up to approximately 70 weeks), and during follow-up period (up to approximately 24 months)
Percentage of Participants Who Report a Clinically Meaningful Improvement in Patient-Reported Function (Social)
A clinically meaningful improvement in patient-reported function and HRQoL was defined as a \>10-point increase from the linearly transformed 0-100 point baseline scale score on each of the four functional (physical, role, emotional, social) scales and global health status/HRQoL scale of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 (QLQ-C30).
Time frame: From randomization to the end of treatment/discontinuation (up to approximately 70 weeks), and during follow-up period (up to approximately 24 months)
Percentage of Participants Who Report a Clinically Meaningful Improvement in Patient-Reported Function (Emotional)
A clinically meaningful improvement in patient-reported function and HRQoL was defined as a \>10-point increase from the linearly transformed 0-100 point baseline scale score on each of the four functional (physical, role, emotional, social) scales and global health status/HRQoL scale of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 (QLQ-C30).
Time frame: From randomization to the end of treatment/discontinuation (up to approximately 70 weeks), and during follow-up period (up to approximately 24 months)
Pecentage of Participants Who Report a Clinically Meaningful Improvement in Patient-Reported Health Related Quality of Life (HRQoL)
A clinically meaningful improvement in patient-reported function and HRQoL was defined as a \>10-point increase from the linearly transformed 0-100 point baseline scale score on each of the four functional (physical, role, emotional, social) scales and global health status/HRQoL scale of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 (QLQ-C30).
Time frame: From randomization to the end of treatment/discontinuation (up to approximately 70 weeks), and during follow-up period (up to approximately 24 months)
Percentage of Participants With Adverse Events (AEs)
Time frame: From randomization up to 90 days after last dose of study treatment or until initiation of new anti-cancer therapy (up to approximately 76 weeks)
This study was conducted at 16 centers in mainland China.
| Milestone | Placebo + Paclitaxel + Carboplatin | Bevacizumab + Paclitaxel + Carboplatin |
|---|---|---|
| Started | 49 | 51 |
| Completed | 0 | 0 |
| Not completed | 49 | 51 |
| Withdrew: Death | 19 | 13 |
| Withdrew: Lost to follow-up | 1 | 2 |
| Withdrew: Withdrawal by subject | 1 | 2 |
| Withdrew: Study ended by sponsor | 28 | 34 |
PFS was defined as time from randomization to the first occurrence of disease progression, as assessed by the Investigator using RECIST v1.1, or death from any cause, whichever occurs first.
| months | Placebo + Paclitaxel + Carboplatin | Bevacizumab + Paclitaxel + Carboplatin |
|---|---|---|
| Progression-Free Survival (PFS) | 12.32 (9.53 to 15.05) | 22.57 (18.60 to NA) |
OS was defined as the time from the date of randomization to the date of death from any cause.
| months | Placebo + Paclitaxel + Carboplatin | Bevacizumab + Paclitaxel + Carboplatin |
|---|---|---|
| Overall Survival (OS) | 48.89 (40.31 to NA) | NA (NA to NA) |
ORR was defined as the proportion of participants with complete response (CR) or partial response (PR) as assessed by investigator according to RECIST v.1.1.
| percentage of participants | Placebo + Paclitaxel + Carboplatin | Bevacizumab + Paclitaxel + Carboplatin |
|---|---|---|
| Objective Response Rate (ORR) | 92.9 (76.50 to 99.12) | 95.8 (78.88 to 99.89) |
DOR was defined as the time from when response (CR or PR) was first documented to first documented disease progression,as assessed by the Investigator using RECIST v1.1, or death from any cause, whichever occurred first. DOR was evaluated for participants who had a objective response of CR or PR.
| months | Placebo + Paclitaxel + Carboplatin | Bevacizumab + Paclitaxel + Carboplatin |
|---|---|---|
| Duration of Response (DOR) | 8.87 (7.56 to 13.14) | 16.10 (10.81 to NA) |
A clinically meaningful improvement in patient-reported abdominal pain or bloating was defined as a ≥10-point decrease from the linearly transformed 0-100 point baseline symptom scale score on each of two items from the Abdominal/Gastrointestinal Symptom Scale of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Ovarian Cancer Module (QLQ-OV28).
| percentage of participants | Placebo + Paclitaxel + Carboplatin | Bevacizumab + Paclitaxel + Carboplatin |
|---|---|---|
| Cycle 4 Day 1 | 37.0 (23.21 to 52.45) | 31.3 (18.66 to 46.25) |
| Cycle 7 Day 1 | 40.9 (26.34 to 56.75) | 42.1 (26.31 to 58.18) |
| Cycle 13 Day 1 | 48.4 (30.15 to 66.94) | 40.0 (23.87 to 57.89) |
| Cycle 22 Day 1 | 37.5 (15.20 to 64.57) | 48.0 (27.80 to 68.69) |
| Treatment Completion / Early Termination Visit | 37.8 (23.77 to 53.46) | 45.2 (29.85 to 61.33) |
| Survival Follow Up 3 Months | 37.0 (19.40 to 57.63) | 33.3 (18.56 to 50.97) |
| Survival Follow Up 6 Months | 33.3 (11.82 to 61.62) | 38.1 (18.11 to 61.56) |
| Survival Follow Up 9 Months | 50.0 (15.70 to 84.30) | 46.2 (19.22 to 74.87) |
| Survival Follow Up 12 Months | 14.3 (0.36 to 57.87) | 42.9 (9.90 to 81.59) |
| Survival Follow Up 18 Months | — | 66.7 (9.43 to 99.16) |
| Survival Follow Up 24 Months | — | 0 (0 to 97.50) |
A clinically meaningful improvement in patient-reported abdominal pain or bloating was defined as a ≥10-point decrease from the linearly transformed 0-100 point baseline symptom scale score on each of two items from the Abdominal/Gastrointestinal Symptom Scale of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Ovarian Cancer Module (QLQ-OV28).
| percentage of participants | Placebo + Paclitaxel + Carboplatin | Bevacizumab + Paclitaxel + Carboplatin |
|---|---|---|
| Cycle 4 Day 1 | 26.1 (14.27 to 41.13) | 33.3 (20.40 to 48.41) |
| Cycle 7 Day 1 | 36.4 (22.41 to 52.23) | 47.4 (30.98 to 64.18) |
| Cycle 13 Day 1 | 29.0 (14.22 to 48.04) | 31.4 (16.85 to 49.29) |
| Cycle 22 Day 1 | 25.0 (7.27 to 52.38) | 40.0 (21.13 to 61.33) |
| Treatment Completion / Early Termination Visit | 33.3 (20.00 to 48.95) | 33.3 (19.57 to 49.55) |
| Survival Follow Up 3 Months | 25.9 (11.11 to 46.28) | 33.3 (18.56 to 50.97) |
| Survival Follow Up 6 Months | 46.7 (21.27 to 73.41) | 19.0 (5.45 to 41.91) |
| Survival Follow Up 9 Months | 25.0 (3.19 to 65.09) | 23.1 (5.04 to 53.81) |
| Survival Follow Up 12 Months | 28.6 (3.67 to 70.96) | 28.6 (3.67 to 70.96) |
| Survival Follow Up 18 Months | — | 66.7 (9.43 to 99.16) |
| Survival Follow Up 24 Months | — | 0 (0 to 97.50) |
A clinically meaningful improvement in patient-reported function and HRQoL was defined as a \>10-point increase from the linearly transformed 0-100 point baseline scale score on each of the four functional (physical, role, emotional, social) scales and global health status/HRQoL scale of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 (QLQ-C30).
| percentage of participants | Placebo + Paclitaxel + Carboplatin | Bevacizumab + Paclitaxel + Carboplatin |
|---|---|---|
| Cycle 4 Day 1 | 17.4 (7.82 to 31.42) | 16.7 (7.48 to 30.22) |
| Cycle 7 Day 1 | 18.2 (8.19 to 32.71) | 18.4 (7.74 to 34.33) |
| Cycle 13 Day 1 | 45.2 (27.32 to 63.97) | 34.3 (19.13 to 52.21) |
| Cycle 22 Day 1 | 43.8 (19.75 to 70.12) | 36.0 (17.97 to 57.48) |
| Treatment Completion / Early Termination Visit | 31.1 (18.17 to 46.65) | 31.0 (17.62 to 47.09) |
| Survival Follow Up 3 Months | 44.4 (25.48 to 64.67) | 27.8 (14.20 to 45.19) |
| Survival Follow Up 6 Months | 13.3 (1.66 to 40.46) | 23.8 (8.22 to 47.17) |
| Survival Follow Up 9 Months | 12.5 (0.32 to 52.65) | 23.1 (5.04 to 53.81) |
| Survival Follow Up 12 Months | 14.3 (0.36 to 57.87) | 28.6 (3.67 to 70.96) |
| Survival Follow Up 18 Months | — | 0 (0 to 70.76) |
| Survival Follow Up 24 Months | — | 0 (0 to 97.50) |
A clinically meaningful improvement in patient-reported function and HRQoL was defined as a \>10-point increase from the linearly transformed 0-100 point baseline scale score on each of the four functional (physical, role, emotional, social) scales and global health status/HRQoL scale of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 (QLQ-C30).
| percentage of participants | Placebo + Paclitaxel + Carboplatin | Bevacizumab + Paclitaxel + Carboplatin |
|---|---|---|
| Cycle 4 Day 1 | 34.8 (21.35 to 50.25) | 31.3 (18.66 to 46.25) |
| Cycle 7 Day 1 | 25.0 (13.19 to 40.34) | 36.8 (21.81 to 54.01) |
| Cycle 13 Day 1 | 45.2 (27.32 to 63.97) | 48.6 (31.38 to 66.01) |
| Cycle 22 Day 1 | 50.0 (24.65 to 75.35) | 40.0 (21.13 to 61.33) |
| Treatment Completion / Early Termination Visit | 40.0 (25.70 to 55.67) | 42.9 (27.72 to 59.04) |
| Survival Follow Up 3 Months | 48.1 (28.67 to 68.05) | 33.3 (18.56 to 50.97) |
| Survival Follow Up 6 Months | 40.0 (16.34 to 67.71) | 42.9 (21.82 to 65.98) |
| Survival Follow Up 9 Months | 37.5 (8.52 to 75.51) | 30.8 (9.09 to 61.43) |
| Survival Follow Up 12 Months | 42.9 (9.90 to 81.59) | 57.1 (18.41 to 90.10) |
| Survival Follow Up 18 Months | — | 33.3 (0.84 to 90.57) |
| Survival Follow Up 24 Months | — | 0 (0 to 97.50) |
A clinically meaningful improvement in patient-reported function and HRQoL was defined as a \>10-point increase from the linearly transformed 0-100 point baseline scale score on each of the four functional (physical, role, emotional, social) scales and global health status/HRQoL scale of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 (QLQ-C30).
| percentage of participants | Placebo + Paclitaxel + Carboplatin | Bevacizumab + Paclitaxel + Carboplatin |
|---|---|---|
| Cycle 4 Day 1 | 28.3 (15.99 to 43.46) | 29.2 (16.95 to 44.06) |
| Cycle 7 Day 1 | 27.3 (14.96 to 42.79) | 28.9 (15.42 to 45.90) |
| Cycle 13 Day 1 | 38.7 (21.85 to 57.81) | 28.6 (14.64 to 46.30) |
| Cycle 22 Day 1 | 43.8 (19.75 to 70.12) | 36.0 (17.97 to 57.48) |
| Treatment Completion / Early Termination Visit | 28.9 (16.37 to 44.31) | 33.3 (19.57 to 49.55) |
| Survival Follow Up 3 Months | 33.3 (16.52 to 53.96) | 47.2 (30.41 to 64.51) |
| Survival Follow Up 6 Months | 26.7 (7.79 to 55.10) | 28.6 (11.28 to 52.18) |
| Survival Follow Up 9 Months | 37.5 (8.52 to 75.51) | 7.7 (0.19 to 36.03) |
| Survival Follow Up 12 Months | 28.6 (3.67 to 70.96) | 28.6 (3.67 to 70.96) |
| Survival Follow Up 18 Months | — | 66.7 (9.43 to 99.16) |
| Survival Follow Up 24 Months | — | 100 (2.50 to 100) |
A clinically meaningful improvement in patient-reported function and HRQoL was defined as a \>10-point increase from the linearly transformed 0-100 point baseline scale score on each of the four functional (physical, role, emotional, social) scales and global health status/HRQoL scale of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 (QLQ-C30).
| percentage of participants | Placebo + Paclitaxel + Carboplatin | Bevacizumab + Paclitaxel + Carboplatin |
|---|---|---|
| Cycle 4 Day 1 | 8.7 (2.42 to 20.79) | 22.9 (12.03 to 37.31) |
| Cycle 7 Day 1 | 13.6 (5.17 to 27.35) | 21.1 (9.55 to 37.32) |
| Cycle 13 Day 1 | 9.7 (2.04 to 25.75) | 25.7 (12.49 to 43.26) |
| Cycle 22 Day 1 | 18.8 (4.05 to 45.65) | 28.0 (12.07 to 49.39) |
| Treatment Completion / Early Termination Visit | 11.1 (3.71 to 24.05) | 21.4 (10.30 to 36.81) |
| Survival Follow Up 3 Months | 22.2 (8.62 to 42.26) | 27.8 (14.20 to 45.19) |
| Survival Follow Up 6 Months | 6.7 (0.17 to 31.95) | 38.1 (18.11 to 61.56) |
| Survival Follow Up 9 Months | 12.5 (0.32 to 57.87) | 38.5 (13.86 to 68.42) |
| Survival Follow Up 12 Months | 14.3 (0.36 to 57.87) | 28.6 (3.67 to 70.96) |
| Survival Follow Up 18 Months | — | 0 (0 to 70.76) |
| Survival Follow Up 24 Months | — | 0 (0 to 97.50) |
A clinically meaningful improvement in patient-reported function and HRQoL was defined as a \>10-point increase from the linearly transformed 0-100 point baseline scale score on each of the four functional (physical, role, emotional, social) scales and global health status/HRQoL scale of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 (QLQ-C30).
| percentage of participants | Placebo + Paclitaxel + Carboplatin | Bevacizumab + Paclitaxel + Carboplatin |
|---|---|---|
| Cycle 4 Day 1 | 19.6 (9.36 to 33.91) | 33.3 (20.40 to 48.41) |
| Cycle 7 Day 1 | 34.1 (20.49 to 49.92) | 34.2 (19.63 to 51.35) |
| Cycle 13 Day 1 | 38.7 (21.85 to 57.81) | 34.3 (19.13 to 52.21) |
| Cycle 22 Day 1 | 43.8 (19.75 to 70.12) | 44.0 (24.40 to 65.07) |
| Treatment Completion / Early Termination Visit | 31.1 (18.17 to 46.65) | 40.5 (25.63 to 56.72) |
| Survival Follow Up 3 Months | 29.6 (13.75 to 50.18) | 38.9 (23.14 to 56.54) |
| Survival Follow Up 6 Months | 33.3 (11.82 to 61.62) | 28.6 (11.28 to 52.18) |
| Survival Follow Up 9 Months | 12.5 (0.32 to 52.65) | 23.1 (5.04 to 53.81) |
| Survival Follow Up 12 Months | 14.3 (0.36 to 57.87) | 42.9 (9.90 to 81.59) |
| Survival Follow Up 18 Months | — | 33.3 (0.84 to 90.57) |
| Survival Follow Up 24 Months | — | 0 (0 to 97.50) |
| percentage of participants | Placebo + Paclitaxel + Carboplatin | Bevacizumab + Paclitaxel + Carboplatin |
|---|---|---|
| Percentage of Participants With Adverse Events (AEs) | 100 | 100 |
Collected over All-cause mortality: From randomization up to end of follow up (54.1 months) AEs and SAEs: From randomization up to 90 days after last dose of study treatment or until initiation of new anti-cancer therapy (up to approximately 76 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo + Paclitaxel + Carboplatin | 19/50 (38%) | 16/50 (32%) | 49/50 (98%) |
| Bevacizumab + Paclitaxel + Carboplatin | 13/49 (26.5%) | 17/49 (34.7%) | 49/49 (100%) |
| Event | Placebo + Paclitaxel + Carboplatin | Bevacizumab + Paclitaxel + Carboplatin |
|---|---|---|
| MyelosuppressionBlood and lymphatic system disorders | 5/50 | 4/49 |
| Platelet count decreasedInvestigations | 5/50 | 3/49 |
| AnaemiaBlood and lymphatic system disorders | 3/50 | 0/49 |
| Neutrophil count decreasedInvestigations | 3/50 | 0/49 |
| IleusGastrointestinal disorders | 1/50 | 2/49 |
| Intestinal obstructionGastrointestinal disorders | 2/50 | 2/49 |
| GranulocytopeniaBlood and lymphatic system disorders | 0/50 | 1/49 |
| Mechanical ileusGastrointestinal disorders | 0/50 | 1/49 |
| NauseaGastrointestinal disorders | 0/50 | 1/49 |
| Pancreatitis acuteGastrointestinal disorders | 0/50 | 1/49 |
| Event | Placebo + Paclitaxel + Carboplatin | Bevacizumab + Paclitaxel + Carboplatin |
|---|---|---|
| AlopeciaSkin and subcutaneous tissue disorders | 41/50 | 43/49 |
| Neutrophil count decreasedInvestigations | 32/50 | 39/49 |
| AnaemiaBlood and lymphatic system disorders | 35/50 | 38/49 |
| White blood cell count decreasedInvestigations | 29/50 | 38/49 |
| Platelet count decreasedInvestigations | 26/50 | 29/49 |
| NauseaGastrointestinal disorders | 25/50 | 20/49 |
| ProteinuriaRenal and urinary disorders | 3/50 | 22/49 |
| VomitingGastrointestinal disorders | 21/50 | 13/49 |
| Alanine aminotransferase increasedInvestigations | 19/50 | 17/49 |
| HypertensionVascular disorders | 9/50 | 18/49 |
| Age, Continuous(years) | Placebo + Paclitaxel + Carboplatin | Bevacizumab + Paclitaxel + Carboplatin | Total |
|---|---|---|---|
| Mean | 53.1 ± 8.4 | 54.1 ± 8.2 | 53.6 ± 8.3 |
| Sex: Female, Male(Participants) | Placebo + Paclitaxel + Carboplatin | Bevacizumab + Paclitaxel + Carboplatin | Total |
|---|---|---|---|
| Female | 49 | 51 | 100 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Placebo + Paclitaxel + Carboplatin | Bevacizumab + Paclitaxel + Carboplatin | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 49 | 51 | 100 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo + Paclitaxel + Carboplatin | Bevacizumab + Paclitaxel + Carboplatin | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 49 | 51 | 100 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2018 to primary completion in May 2021, 33 months.
Results were first posted in Mar 2023, 1 year 9 months after primary completion.
Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's 33 months is below that.
Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bevacizumab